STAT+: Startup promising to scale custom CRISPR therapies abruptly scraps plans
STAT News · LC · trust 41/100
The FDA, while promising flexibility in approving Baby KJ-type gene editing, still has set standards difficult for a small startup to meet.
Read the original at STAT News →
Open in TruthVane →